Business
Resverlogix Announces Dr. H. Bryan Brewer Joins Clinical Steering Committee
Jun. 23, 2011 (Canada NewsWire Group) -- CALGARY, June 23, 2011 /CNW/ - Mr. Don McCaffrey, Pr...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n Jun. 23, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nCALGARY, June 23, 2011 /CNW/ - Mr. Don McCaffrey, President and CEO of\n Resverlogix Corp. (TSX:RVX) is pleased to announce today the addition\n of Professor H. Bryan Brewer to Resverlogix's Clinical Steering\n Committee.  Professor Brewer, a cardiologist, is currently the Director\n of Lipoprotein and Atherosclerosis Research, Cardiovascular Research\n Institute, Washington Hospital Center, Washington, D.C., USA. \n Professor Brewer was the former Chief of the Molecular Disease Branch\n at the National Institute of Health, Bethesda, MD, USA and is a leader\n and pioneer in the field of high density lipoprotein (HDL) research. \n His seminal observations led to the cloning of the Apolipoprotein A-I\n (ApoA-I) mRNA and the gene.  The availability of the ApoA-I mRNA and\n gene enabled clinicians and scientists to understand the role of ApoA-I\n protein in reverse cholesterol transport (RCT) and atherosclerosis\n protection. \n\n\n"Professor Brewer is one of the most well respected pioneers in the\n field of HDL biology.  He has extensive industry expertise having\n served as a consultant to major pharmaceutical companies including\n Abbott, Lilly, Merck, Pfizer, Roche, Sanofi-Aventis and\n Schering-Plough.  These skills will enhance the activities of our\n Clinical Steering Committee which is instrumental in the design and\n conduct of Resverlogix's human clinical trials relati...